DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

HIMS·Hims & Hers Health, Inc.

$.
-. (-.%)
After Hours
High
$28.25
Open
$27.10
Market Cap
6.06B
52W High
$70.43
Low
$25.40
P. Close
$26.16
P/E
47.22
52W Low
$13.74
Fwd P/E
20.36
DailyIQ Est.
-
Technical Score (1D)
64
BUY
News Sentiment
41
BEARISH
Hims & Hers Health’s latest earnings show a sharp revenue uptick driven by its GLP‑1 compounding service, a segment that has been the main engine of growth in the past quarter. The surge comes as the company’s GLP‑1 supply chain remains tight, but analysts warn that the shortage could ease soon, potentially curbing the revenue momentum that has buoyed the stock. The firm’s valuation remains steep, with a trailing P/E of 57 and a forward P/E near 59, implying that any slowdown in GLP‑1 demand could quickly erode the premium investors are paying. In addition, Hims & Hers is embroiled in a legal gray area that could expose it to regulatory scrutiny, especially if the company’s compounding practices are deemed to conflict with Novo Nordisk’s licensing terms. The combination of a potentially fragile growth driver and a high valuation means that the next 1–10 trading days will be a litmus test for the sustainability of the GLP‑1 business. If the GLP‑1 shortage persists, the company may need to accelerate its broader telehealth portfolio to offset any decline, which could dilute earnings per share. Conversely, a rapid easing of the shortage could force Hims & Hers to pivot to alternative revenue streams, potentially impacting its cost structure and profitability. Investors should monitor the company’s quarterly guidance for any changes in GLP‑1 volume projections and watch for regulatory filings that could clarify the legal dispute with Novo Nordisk. A clear signal from Hims & Hers regarding its strategy to diversify beyond GLP‑1 will be the key watch item for the coming week, as it will determine whether the current valuation remains justified.
Earnings Summary
Company Context: Hims & Hers Health, Inc. operates a telehealth platform that delivers direct‑to‑consumer prescription medications, ongoing care, and a range of over‑the‑counter wellness products through its online portal and mobile app. The company positions itself as a comprehensive health ecosystem within the specialty drug and consumer health sector, blending medical services with curated product lines. Recent Quarterly Performance: In Q4 2025 Hims reported earnings of $0.07 per share on $617.8 million in revenue, a slight decline from the $0.17 EPS and $544.8 million revenue seen in Q2 2025, and a modest $10.2 % revenue rise from Q2 to Q3 2025. The Q1 2026 quarter saw a further EPS drop to –$0.18 on $608.1 million revenue, marking the first quarterly loss in the data set and a 1.5 % revenue decline versus Q4 2025. Historically the company has posted three consecutive earnings beats (Q4 2024, Q1 2025, Q2 2025) before experiencing a streak of misses (Q3 2025, Q4 2025, Q1 2026), with revenue growth persisting through the first three quarters despite the recent EPS downturn. Historical Streak Analysis: Year‑over‑year revenue has accelerated from $544.8 million in Q2 2025 to $598.9 million in Q3 2025 (+10.2 %) and then to $617.8 million in Q4 2025 (+3.1 %), but fell to $608.1 million in Q1 2026. EPS has trended downward from $0.17 in Q2 2025 to $0.06 in Q3 2025, to $0.07 in Q4 2025, and to a loss in Q1 2026, underscoring a shift from profitability to a loss position. Recent News Context: The company’s acquisition of Eucalyptus has expanded its telehealth footprint into Japan, Germany, Canada, and Australia, adding weight‑management services and a robust clinical network that could broaden recurring revenue and lower acquisition costs. Analysts are monitoring the integration pace and GLP‑1 margin assumptions, as early revenue contributions from the German weight‑management segment are expected to lift earnings. Forward‑Looking Watch Points: Investors should watch for the first quarterly earnings rebound and the impact of international expansion on revenue, particularly the early performance of the German and Canadian segments, as well as any updates on GLP‑1 margin assumptions and regulatory approvals that could influence short‑term cash flow.

EPS

EstBeatMiss
$-0.24$-0.10$0.03$0.17$0.31Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.13 - -
Q1'26$0.13$-0.18-235.8%
Q4'25$0.25$0.07-71.9%
Q3'25$0.10$0.06-41.0%
Q2'25$0.16$0.17+3.2%
Q1'25$0.12$0.20+65.0%

Revenue

EstBeatMiss
$521M$573M$624M$675M$727MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$703M - -
Q1'26$629M$608M-3.4%
Q4'25$653M$618M-5.3%
Q3'25 - $599M -
Q2'25 - $545M -
Q1'25 - $586M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

HIMS Stock Snapshot

HIMS is currently trading at $25.86, giving Hims & Hers Health, Inc. a market cap of 6.06B and a P/E ratio of 47.2. Today's range spans $25.40–$28.25, with shares opening at $27.10 and moving down $0.30 (1.1%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 41/100.

Over the past year HIMS has traded between $13.74 and $70.43 - the current price is +88.2% off the 52-week low and -63.3% from the high.

Small-cap Healthcare names like HIMS are high-beta on sentiment - and right now, sentiment is neutral (41/100). Technical score: 64/100 (HOLD). Price: $25.86 (in the lower half of its 52-week range). (P/E: 47.2) At 6.06B in market cap, the 52-week range of $13.74–$70.43 is where the risk gets real: stocks at this size can cover the full range on a single catalyst, in either direction. The current setup doesn't yet show the ingredients for a positive one.

For HIMS (small-cap, Healthcare, 6.06B market cap), the HOLD technical reading (64/100) and neutral news sentiment (41/100) at $25.86 (in the lower half of its 52-week range) describe a stock where the cost of patience is higher than in large-cap equivalents — thin float dynamics mean that time spent waiting for a catalyst can erode position value without the passive bid support that larger names receive. The $13.74–$70.43 annual range defines the structural stakes.